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Trapidil inhibits human mesangial cell proliferation: Effect on PDCF
a-receptor binding and expression. Mesangial cell (MC) proliferation, a
histopathologic feature common to many human glomerular diseases, is
regulated by several growth factors through their binding to specific cell
surface receptors. Platelet-derived growth factor (PDGF) is a peptide
exerting a potent mitogenic activity on MC. Recently, an increased
expression of both PDGF protein and its receptor has been localized in
the mesangial areas of several experimental as well as human proliferative
glomerulonephritides (GN). Thus, it may be postulated that the inhibition
of PDGF action could prevent MC proliferation during mesangial prolif-
erative GN. Trapidil, an antiplatelet drug, has been shown to inhibit the
growth of several cell types both in vitro and in vivo. The present study was
aimed at evaluating the effect of Trapidil on human MC in vitro. The
addition of 100 to 400 jsg/ml Trapidil significantly reduced cell prolifera-
tion induced by different growth factors (FCS, PDGF-BB, bFGF, EGF),
the highest inhibitory effect being on PDGF-BB stimulated MC growth.
The effect of the drug was dose-dependent and seemingly specific: aspirin
was devoid of any anti-proliferative action, while dypiridamole proved to
be toxic. Receptor binding experiments showed that Trapidil competitively
inhibited 251-PDGF-BB binding to its cell surface receptors, without
inducing receptor internalization, at least after short-term (2 hr) incuba-
tion. In contrast, long-term (48 hr) exposure to 400 pg/mI Trapidil caused
a sharp increase of PDGF-BB binding. Similar effects on cell proliferation
and 25I-PDGF-BB binding were observed when NIH-3T3 fibroblasts were
exposed to the test substance. Finally, we evaluated the influence of
Trapidil on PDGF 13-receptor gene expression and found that 24 hour
exposure to 400 pg/mI Trapidil moderately decreased steady-state mRNA
levels, whereas 48 hours of incubation increased PDGF 13-receptor
transcript levels by approximately threefold. We conclude that Trapidil is
able to strongly inhibit human MC proliferation, a process in which
inhibition of PDGF-BB binding to its receptors and modulation of PDGF
J3-receptor gene expression might be involved.
Platelet-derived growth factor (PDGF) exerts a striking mitogenic
activity on mesangial cells (MC), along with a broad range of
biological effects, including chemoattraction and regulation of
matrix metabolism [1—4]. All these biological activities are medi-
ated through the binding of the growth factor to cell surface
receptors, which transduce extracellular events into intracellular
biochemical signals [4, 5—13]. Interestingly, multiple peptide
growth factors, and PDGF itself, induce PDGF-A and -B chain
mRNA in MC [14]. This suggests that endogenous PDGF may
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mediate, at least in part, the biological effect of other growth
factors, as demonstrated for EGF, and elects PDGF as a potential
autocrine regulator of MC proliferation [14].
MC play a pivotal role in the course of glomerular injury: they
first act as target cells for several mediators, which are released
locally or are delivered through the systemic circulation [4, 15, 16].
Thereafter, they may drive the evolution of pathologic lesions
towards resolution or progression of the glomerular disease. MC
proliferation, a histopatologic feature common to different forms
of glomerulonephritides [17], is likely to influence the regulation
of glomerular microvascular system and extracellular matrix pro-
duction.
Several experimental as well as human proliferative glomeru-
lonephritides were shown to display an increased expression of
both PDGF protein and its receptor in mesangial cells [18—24].
These data indicate PDGF as a growth factor primarily implicated
in the pathogenesis of mesangial proliferative glomerulonephrit-
ides. Consequently, it may be postulated that the inhibition of
PDGF action could prevent MC proliferation and the activation
of other growth factor pathways during mesangial proliferative
glomerulonephritides.
Trapidil is an anti-platelet drug active against various aggregat-
ing agents, such as collagen, ADP, arachidonic acid, PAF and
calcium ionophore [25, 26]. It exerts its action by blocking the
biosynthesis of thromboxane A2 and antagonizing its effect at the
receptor level, and by stimulating the synthesis and release of
prostacyclin [25, 26]. Moreover, Trapidil has been shown to inhibit
the growth of several cell types both in vitro and in vivo [27—31].
In the present study, we have explored the possibility that
Trapidil exerts an antiproliferative effect on human MC in vitro.
We show that the drug is able to strongly inhibit cell growth and
that it interferes with the binding of PDGF-BB to its receptor and
with the regulation of PDGF 13-receptor transcript levels.
Methods
Cell culture
Human MC lines were established employing a modification of
a previously published technique [32]. Glomeruli were isolated
from histologically normal portions of human kidneys, obtained at
the time of nephrectomy for renal carcinoma, by passage through
serially graded sieves (425 and 180 jrm-mesh brass filters) and
collection on 75 rm-mesh nylon filters. The glomeruli were
decapsulated by forced flow through a 18-gauge needle, washed
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Fig. 1. Effect of Trapidil on human MC growth.
Cells were serum- and insulin-starved for 48
hours. Thereafter, they were challenged with
either 10% FBS (A), 20 ng/ml PDGF-BB (B), 10
ng/ml bFGF (C) or 20 ng/ml EGF (D), in the
presence or absence of different concentrations of
Trapidil (0: 0 p.g/ml, •: 100 Lg/ml; El: 200 rg/
ml; •: 400 jig/mI). The hatched lines represent
________________
______ human MC growth in the presence of 0.01% FBS
48 °6 (basal). Data are presented as means SEM of 7
experiments, each performed in quadruplicate. *p
< 0.01, 'P < 0.05 versus cell proliferation
Time, hours induced by mitogen alone.
twice, incubated for 30 minutes with 750 U/mI of bacterial
collagenase type IV (Sigma Chemical Co., St. Louis, Missouri,
USA) and finally resuspended in RPM! 1640 medium (Gibco
Laboratories, Grand Island, New York, USA) supplemented with
17% heat-inactivated fetal bovine serum (FBS, Hyclone Labora-
tories, Inc., Logan, Utah, USA), 100 U/mI penicillin, 100 jtg/ml
streptomycin, 2 mi L-glutamine, 2 m sodium pyruvate, 1%
(vol/vol) non-essential amino acids, 5 j.tg/ml insulin, 5 jig/mI
transferrin and 5 ng/mI selenium. In the present study four human
MC lines between passage 4 and 12 were used. NIH 3T3
fibroblasts were provided by Dr. HE. Abboud, and were grown in
the same medium used for HMC.
Morphological and immunohistochemical characterization of
HMC
After passage 3, MC looked like elongated spindle-shaped cells.
No glomerular, endothelial, or epithelial cells were observed, as
judged by phase contrast microscopy. Moreover, the purity of the
culture was assessed by immunoperoxidase staining for interme-
diate filaments and surface antigens. The cells showed an intense
positivity for desmin, laminin and vimentin and were negative for
keratin, factor Vill-related antigens, common leukocyte antigen
(CD 45) and macrophage antigen (CD 68).
Cell counts
Cells (10 cells/well), grown in complete RPMI, were rendered
quiescent by removal of FBS for 72 hours. Serum deprivation did
not affect cell viability as assessed by morphology, Trypan blue
vital dye exclusion test and lactate dehydrogenase (LDH) assay.
After 72 hours of incubation in serum-free medium, cells were
washed once with Hanks' Balanced Salt Solution (HBSS, Gibco
Laboratories) without calcium and magnesium and re-fed with
serum-free medium. Cells were stimulated with several substances
[0.01 to 10% FBS, 20 ng/ml PDGF-BB (Pepro Tech Inc., Rocky
Hill, New Jersey, USA), 10 ng/ml bFGF (Pepro Tech Inc.) or 20
ng/ml EGF (Collaborative Research, Inc., Bedford, Massachu-
setts, USA)] in the presence or absence of Trapidil (Master
Pharma, Parma, Italy), acetylsalicylic acid (ASA, Sigma Chemical
Co.) or dypiridamole (Sigma Chemical Co.). At the selected times
(0 to 96 hours), cell growth was evaluated by cell counting. Briefly,
cells were trypsinized for I to 2 minutes at 37°C. The enzymatic
activity was blocked by the addition of I mI/well of 17% FBS-
supplemented medium. Cell detachment was helped by gentle
abrasion with a plastic scraper and verified by phase-contrast
microscopy. Cell suspension obtained was centrifuged at 600 Xg
and resuspended in Isoton III solution (Coulter Electronics LTD,
Luton, Beds, UK). Finally, cells were counted in a Coulter
Counter (Coulter Electronics LTD). Since PBS and other mito-
gens could occasionally induce cell detachment, cell counting was
also performed on cell supernatants after exposure to mitogens.
Cell viability
Cell viability was determined by Trypan blue dye exclusion test
and LDH assay. Supernatants, collected from cells seeded in
serum-free medium and exposed to the different mitogens and
drugs tested, were centrifuged and LDH concentration deter-
mined. Supernatants obtained from sonicated cells were used as a
positive control. Furthermore, to definitely exclude a cytotoxic
effect of Trapidil on human MC, cells incubated for four days with
and without the drug were challenged with fresh medium contain-
ing 10% FBS, and cell proliferation evaluated.
PDGF-binding experiments
Standard binding assay. Binding experiments were performed
on confluent MC cells (about i0 cells/well), made quiescent by
incubation in serum-free medium for 48 hours. After rinsing with
1 ml binding buffer (RPM! 1640, pIus 25 mt Hepes, pH 7.4, and
2 mg/ml BSA), cells were incubated with 5 ng/ml '251-PDGF-BB
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Fig. 2. Effect of Trapidil on NIH 3T3 fibroblasts proliferation. Cells were
serum- and insulin-starved for 48 hours. Thereafter, they were challenged
with either 10% FBS (A), 20 ng/ml PDGF-BB (B) or 10 ng/ml bFGF (C),
in the presence or absence of different concentrations of Trapidil (0: 0
isg/ml, •: 100 rg/ml; 0: 200 /LgIml; •: 400 jsglml). Data are presented as
mean SCM of 4 experiments, each performed in quadruplicate. °P <
0.05, < 0.01 versus cell proliferation induced by mitogen alone.
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(S.A.: 1000 Ci/mmol, Amity S.r.l., Milan, Italy) for two hours at
4°C, with constant gentle rotatory agitation.
At the end of the incubation period, cells were washed thrice
with ice-cold PBS containing 1 mr't CaCI2 and 2 mg/mi BSA and
then solubilized by adding 1,0 ml of 20 mrvi Hepes, pH 7.4, 1%
Triton X-i00, 10% (vol/vol) glycerol, and 0.1 mg/mI BSA. Cell-
bound radioactivity was counted in a gamma counter. Nonspecific
binding was determined in the presence of a 100-fold excess of
purified PDGF-BB. Specific binding was calculated by subtracting
non specific binding from the total counts bound per well.
Coincubation assay. HMC were incubated for two hours at 4°C
with 1251-PDGF-BB and various concentrations of Trapidil. Then,
cultures were washed thrice in ice-cold binding buffer. Cell
associated 1251 radioactivity was extracted as described above.
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Sequential assay. HMC were preincubated with various concen-
trations of Trapidil for two hours at 37°C. Thereafter, cultures
were extensively washed in ice-cold binding buffer and standard
binding assay was then performed. In some experiments, cells
were exposed to 400 jrg/ml Trapidil for 48 hours at 37°C. HMC
were subsequently rinsed four times in 4 ml of ice-cold binding
buffer, before performing binding experiments.
Acid washing assay. These experiments were aimed to deter-
mine whether the competing activity of Trapidil on PDGF-BB
binding could be removed by acid washing of HMC. To this aim,
cells were preincubated with Trapidil for two hours at either 4° or
37°C, then washed with binding medium and subsequently ex-
posed to medium containing 0.1% acetic acid (pH 3.52) with 150
mM NaCI and 2 mg/ml BSA for eight minutes at 4°C {2, 33, 4I.
0 100 200 400 800
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Fig. 3. Effect of Trapidil on '251-PDGF-i3B binding to lIAR and ,VlH 3T3
fibroblasts. A. Coincuhation assay. Human MC were incubated with S
nglmt '2-I-PDGF-BB and (Ho 8(X) sg/ml Trapidil for 2 hours at 4 C. Then.
ccli associated radu,aeti ity was determined. 8. Sequential assay. Human
MC were preincubated with the indicated concentrations at Trapidil for 2
hours at 3TC. Thereafter, cells were extensively washed with binding
medium and specific PDGF 138 binding wu measured. C. Sequential assay
performed on Nil-i 3T3 libroblasts. Data are given as the means t il) of
three separate experiments. each perlhrmed in quadruplicate. */) < 01)5,
"P C 0.01 versus control.
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Cells were extensively washed with binding medium and 125J
PDGF binding was then determined as described above.
RNA isolation and Northern analysis
Human MC were rested for 48 hours in serum-free medium and
then incubated for 0 to 48 hours with 20 ng/ml PDGF BB in the
presence or absence of 400 g/ml Trapidil. Cells were lysed with
4 M guanidium isothiocyanate containing 25 m sodium citrate,
pH 7.0, 0.5% sarcosyl and 0.1 ms 2-3-mercaptoethanol. Total
RNA was isolated by the single-step method, using phenol and
chioroform/isoamylalcohol, as previously described [35]. Levels of
PDGF /3-receptor mRNA were determined by Northern analysis,
using a 751 base pair fragment of the human PDGF 13-receptor
eDNA [36], isolated from pGEM-1 plasmid with Pst I. The eDNA
was labeled with (32P) dCTP (3,000 Ci/mmol, Amersham, UK)
using random primer extension and added at 1 X 106 cpm/ml.
Electrophoresis of 20 tg of total RNA was carried out in 1%
agarose gel with 2.2 M formaldehyde. The RNA was then trans-
ferred overnight to a nylon membrane (Schleicher & Sehuell,
Dassel, Germany). Prehybridization and hybridization were per-
formed for 18 hours at 42°C in a buffer containing 50% form-
amide, 5xSSC, 5x Denhart's solution, 0.1% SDS, 100 g/ml
denatured salmon sperm DNA. The blots were then washed once
in 2x SSC, 0.1% SDS at 22°C for five minutes, and once in the
same buffer at 55°C for 30 minutes, Finally, the membranes were
washed in lx SSC, 0.1% SDS at 55°C for a further 30 minutes.
After drying, membranes were exposed to a Kodak X-OMAT film
with intensifying screens at —70°C. Membranes were subsequently
stripped and rehybridized with a (32P)-labeled glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) eDNA probe, added at 2 X
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Fig. 4. Effect of chronic exposure to Trapidi! on '251-PDGF-BB binding.
Human MC were incubated with 400 jLg/ml Trapidil for 48 hours at 37°C.
Thereafter, cells were rinsed 4 times in 4 ml of ice-cold binding medium,
before performing binding experiments. °P < 0.01 versus control.
I 0 cpm/ml, to account for small differences in RNA loading and
transfer.
Statistical analysis
Dose- and time-response curves of cell counts were analyzed by
two-way analysis of variance on raw data. Receptor binding
experiments were analyzed by unpaired Student's t-test.
Results
Several growth factors (FBS, PDGF-BB, bFGF and EGF) were
able to stimulate human MC proliferation, with PDGF resulting
as the most potent mitogen after FBS (Fig. 1). The addition of
Trapidil caused a growth inhibition that was dose-dependent (Fig.
I). After 96 hours of incubation with 100 xWml Trapidil, average
inhibition of cell proliferation induced by either FBS, PDGF-BB,
bFGF or EGF was 41.8, 65.3, 38.7 and 56%, respectively. It is
therefore apparent that Trapidil exerted its maximum inhibitory
effect on PDGF-stimulated cells (Fig. IB).
Aspirin, at the same doses of Trapidil, was devoid of any
significant effect: 100 jxg/ml aspirin inhibited PDGF-BB-induced
cell proliferation by 6.8 3.2% after 96 hours. Dypiridamole
resulted in being toxic for human MC: at doses of 10 to 100 iM (5
to 50 agJml), comparable to those used in other cell culture
systems, it induced cell lysis, as confirmed by LDH assay.
Trypan blue dye exclusion test, LDH assay of cell supernatants
as well as the rapid increase of cell proliferation following the
challenge with fresh 10% FBS-supplemented medium demon-
strated that the drug was devoid of any cytotoxic effect on human
MC in culture (data not shown). Noteworthy, Trapidil did not
induce any significant variation in cell detachment at the doses
tested, compared to FBS-stimulated cells.
We next analyzed whether the anti-proliferative effect of Tra-
pidil was specific for human MC. To this aim, NIH 3T3 fibroblasts
were challenged with FBS, PDGF or bFGF and the effect of
Trapidil was then tested. Figure 2 demonstrates that Trapidil also
affected fibroblast growth, with a dose-dependent fashion. Note
that, at comparable concentrations, the drug exhibited its highest
inhibitory effect towards PDGF-BB-induced cell growth.
Previous investigations focused on PDGF antagonistic effect of
Trapidil and postulated an inhibition of PDGF interaction with
target cells. Therefore, we wondered whether Trapidil might
interfere with the first step of the chain of events leading to cell
activation by PDGF, namely the binding of the growth factor to
specific cell surface receptors. Figure 3A shows that Trapidil
inhibited specific binding of '251-PDGF-BB to human MC, when
both ligands were added simultaneously (coincubation assay).
This assay does not allow distinction between inhibition result-
ing from an interaction between Trapidil and PDGF receptor and
inhibition resulting from a direct interaction of the test substance
with the growth factor. Preincubation of cells with Trapidil alone,
followed by extensive washing and then exposure to labeled ligand
(sequential assay) enables discrimination between these two pos-
sibilities and definitely demonstrated that Trapidil exerts its
inhibitory effect by interacting with PDGF receptor (Fig. 3B).
Sequential assay performed on NIH 3T3 fibroblasts yielded
similar results (Fig. 3C).
However, the above findings still raise two possibilities: Trapidil
might inhibit PDGF binding to its cell surface receptor and/or
induce a reduction of receptor number (that is, surface receptor
translocation). To further clarify this issue, human MC were
preincubated with 400 xg/ml Trapidil at either 4 or 37°C;
thereafter the cells were washed at pH 3.52 before measurement
of '251-labeled PDGF binding, to dissociate the drug from cell
binding. Washing the cells with an acidic medium almost com-
pletely reversed the inhibition of PDGF binding, regardless of the
temperature of preincubation (control: 3.45 0.43 fmol/105 cells;
Trapidil-treated cells, 4°C: 3.03 0.250 fmol/105 cells; 37°C: 2.71
0.380 fmol/105 cells; N = 3). Thus, experiments performed with
cells maintained at 37°C yielded a conclusion identical to that
obtained in experiments performed at 4°C, when PDGF receptor
cannot be internalized: Trapidil exerts a fainty effect, if any, on
receptor disappearance from cell surface [2, 33, 34J. Finally,
long-term (48 hr) exposure to 400 jig/mi Trapidil caused a 150%
increase of 1251-PDGF binding to human MC (Fig. 4).
The results of receptor binding experiments prompted us to
investigate the kinetics of Trapidil effect on PDGF-f3 receptor
mRNA. Northern blot analysis of PDGF-f3 receptor transcript
revealed a 30% decrease of PDGF-/3 receptor mRNA levels after
24 hour exposure of PDGF-stimulated human MC to 400 jxg/ml
Trapidil, whereas at 48 hours 3-receptor transcript levels dis-
played an almost threefold increase over control cells (Fig. 5).
Discussion
Cell proliferation assays showed that Trapidil exerts a strong
inhibition of human MC growth induced by different mitogens,
the strongest effect being on PDGF-stimulated cell proliferation.
Similar results were obtained when NIH-3T3 fibroblasts were
analyzed.
Previous reports described a suppression of PDGF-induced
proliferation in different cell culture systems pretreated with
Trapidil [27—31]. Onishi et a! [27] postulated that Trapidil might
function as a competitive inhibitor of PDGF to its receptor, thus
preventing PDGF from inducing its mitogenic effect. On the other
12
5I
PD
G
F 
BB
 b
ou
nd
, I
m
oV
i 0
0,
00
0 
ce
lls
 
-
4 
0 
01
 
0 
01
 
a
 0 0 
PDGF n-receptor
GAPDH
Hours 0 24 48
Trapidil — + — +
Gesualdo et at: Trapidil inhibits MC proliferation 1007
Fig. 5. A. Total RNA was isolated from human MC cultured in
the presence of 20 nglml PDGF-BB and with or without 400
p.gIml Trapidil for up to 48 hours; 20 p.g of RNA foreach time
point was separated in 1% denaturing agarose gel and
transferred to nitrocellulose. The filter was hybridized with a
fragment from PDGF p-receptor cDNA, then stripped and
rehybridized with a glyceraldehyde-phosphate dehydrogenase
(GAPDH) probe, as internal standard, and subjected to
autoradiography. Represented is one of three separate
experiments. B. the hybridization signals obtained in A were
quantified by scanning of autoradiograms and expressed
relative to the level of zero time, after adjusting to the
GAPDH signal.Points are the means of three separate
experiments. Symbols are: (0) PDGF + TRAP; (L) PDGF.
PDGF+TRAP
PDGF
8
7
Time, hours
hand, both EGF and bFGF are able to induce PDGF gene
expression and protein synthesis in MC and would exert their
mitogenic effect, at least in part, via the PDGF loop [31•
Therefore, a unifying hypothesis which postulates that Trapidil
exerts its growth inhibitory effect on different mitogens through
the inhibition of PDGF interaction with target cells appears
intriguing. Indeed, Silver, Jaft'er and Abboud [141 previously
0 24 48
demonstrated that a polyclonal anti-PDGF antibody was able to
inhibit EGF-stimulated mesangial cell growth with a dose-depen-
dent effect. In preliminary experiments, we found that 48-hour
incubation with 2 sg/ml polyclonal anti-PDGF-AB antibody in-
hibited bFGF-induced human MC proliferation by 31%, a value
roughly corresponding to the inhibition exerted by 100 sg/ml
Trapidil.
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Within this frame, inhibition of cellular binding of PDGF by
Trapidil represents the first possible target. Binding inhibition
experiments demonstrated that Trapidil does interfere with
PDGF binding to its cell surface receptors by competitive inhibi-
tion. This conclusion is supported by both sequential radiorecep-
tor assay and acid wash experiments. The latter studies also
suggest that Trapidil does not induce receptors disappearance
from cell surface, at least after short-term incubation.
Simultaneous competition assay showed that the contemporary
addition of PDGF and Trapidil blunted the binding-inhibitory
effect of the drug, and would imply that the test substance displays
a lower affinity for PDGF receptor than the natural ligand. This
conclusion is consistent with the finding of the lack of an
anti-proliferative effect of Trapidil, when its addition is delayed up
to four hours after the exposure of cells to PDGF, and most
available surface receptors are occupied by the natural ligand
(data not shown).
Binding experiments performed after 48 hours of exposure of
HMC to Trapidil revealed a sharp up-regulation of PDGF-BB
binding. Finally, Trapidil was shown to influence the level of
PDGF-/3 receptor transcript in human MC: 24 hours of exposure
to 400 g/ml Trapidil caused a moderate decrease of target gene
expression, whereas at 48 hours Trapidil-treated cells exhibited a
marked increase of specific mRNA transcript, seemingly support-
ing the results of PDGF-BB binding studies. Presently we cannot
explain the latter finding. More specifically, we cannot distinguish
between a direct effect of Trapidil, or its metabolites, on mRNA
transcript levels, or an adaptive response of cells to PDGF
receptor binding-inhibition.
In conclusion, our results demonstrate that Trapidil: (i) exerts
an inhibitory role on human MC and NIH 3T3 fibroblasts growth,
as induced by several growth factors; (ii) competitively antago-
nizes PDGF-BB binding to its specific surface receptors and
modulates f3-receptor transcript levels.
In our opinion the above considerations, while casting some
doubts on the complete mechanism of action of Trapidil, do not
diminish the potential relevance of the findings presented here. In
fact, the available evidence from human and animal studies
supports the view that PDGF is a prime candidate to mediate or
modulate biologic responses of MC to glomerular injury, both
directly and through the activation of other growth factor path-
ways, such as TGF-f3. On the other hand, the PDGF effect is
mediated through the binding to its specific cell surface receptors.
Therefore, any substance able to interfere with the above binding,
even in the presence of high levels of receptor expression, should
inhibit the biologic effect of the natural ligand.
Until now, neomycin is the only agent known to interfere with
the mitogenic effect of PDGF, by specifically blocking only
PDGF-a receptors [38]. Indeed, several studies indicate that both
human and experimental proliferative glomerulonephritides ex-
press a remarkable increase of 13-receptor expression, with only
minor modifications of n-receptor transcript and protein levels
[18—24, 39].
The present study suggests, but does not permit a definite
conclusion, that the anti-proliferative effect of Trapidil is medi-
ated through the interference with PDGF loop. In any event, it
clearly demonstrates that Trapidil blocks PDGF-p receptor inter-
action with the natural ligand on cell surface.
A more comprehensive understanding of the temporal relation-
ship between the expression of different growth factors and the
pathologic manifestations of the disease should help clarify the
role of inhibitory agents (such as Trapidil and other receptor
antagonists, anti-sense oligonucleotides, blocking antibodies, sol-
uble receptors) able to reduce mesangial cell proliferation and the
overall biological effects of growth factors in the treatment of
mesangial proliferative glomerulonephritis.
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